Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy
Urology Oct 18, 2017
Robins D, et al. - As a part of this study, the survival outcomes of patients with muscle-invasive bladder cancer (MIBC) were contemplated, that illustrated a complete clinical response (cT0) to neoadjuvant chemotherapy (NAC) and then rejected the subsequent radical cystectomy (RC). It was reported that bladder preservation could serve as a logical choice in a highly select subset of patients with MIBC, presenting as complete clinical responders following NAC. For those patients that were cT0 after NAC and refused or were ineligible for RC, five-year disease-free survival (DFS) was found to be approximately 60% and cancer-specific survival (CSS) was nearly 90%. In order to determine the clinical and molecular factors related to a durable pathologic complete response after NAC, advanced research was required.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries